PAMELA MUNSTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Phase 1

Recruiting

Conditions: BRCA2 Mutation
BRCA Mutation
PALB2 Gene Mutation
Checkpoint Kinase 2 Gene Mutation
BRCA1 Mutation
ATM Gene Mutation

Interventions: Drug: Olaparib
Drug: ASTX727

First Posted Date: 2023-12-20

Last Posted Date: 2024-05-01

Lead Sponsor: Pamela Munster

Target Recruit Count: 18

Registration Number: NCT06177171

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

Phase 1

Withdrawn

Conditions: PIK3CA Mutation
Solid Tumors, Adult
Human Papillomavirus-Related Carcinoma
Metastatic Malignant Solid Neoplasm
HPV-Related Squamous Cell Carcinoma
PIK3CA Mutation-Related Tumors
Human Papillomavirus-Related Squamous Cell Carcinoma
Locally Advanced Malignant Solid Neoplasm

Interventions: Drug: Alpelisib
Drug: Carboplatin
Drug: Hyperpolarized Carbon-13 (13C) Pyruvate
Device: Continuous Glucose Monitor (CGM)

First Posted Date: 2022-07-25

Last Posted Date: 2022-12-27

Lead Sponsor: Pamela Munster

Registration Number: NCT05472220

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Phase 1

Withdrawn

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Hormone Receptor Positive Breast Carcinoma
Locally Advanced Breast Carcinoma
Metastatic Breast Carcinoma
Metastatic Endometrioid Adenocarcinoma
Metastatic Primary Peritoneal Carcinoma

Interventions: Drug: Abexinostat Tosylate
Drug: Fulvestrant
Drug: Palbociclib

First Posted Date: 2020-08-04

Last Posted Date: 2021-05-18

Lead Sponsor: Pamela Munster

Registration Number: NCT04498520

Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

Phase 1

Completed

Conditions: Solid Tumor, Unspecified, Adult

Interventions: Drug: Rucaparib
Drug: Irinotecan

First Posted Date: 2017-10-23

Last Posted Date: 2021-03-04

Lead Sponsor: Pamela Munster

Target Recruit Count: 22

Registration Number: NCT03318445

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

Early Phase 1

Withdrawn

Conditions: Documented Her2 Overexpression
Advanced Solid Tumor
Brain Metastases
Neurologically Stable

Interventions: Drug: MM-302
Drug: Trastuzumab

First Posted Date: 2016-04-13

Last Posted Date: 2017-05-04

Lead Sponsor: Pamela Munster

Registration Number: NCT02735798

Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: Alpelisib
Drug: Cisplatin

First Posted Date: 2015-12-03

Last Posted Date: 2020-01-10

Lead Sponsor: Pamela Munster

Target Recruit Count: 28

Registration Number: NCT02620839

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Triple Negative Metastatic Breast Cancer
BRCA-mutated Solid Tumor

Interventions: Drug: BMN-673
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2015-02-06

Last Posted Date: 2020-01-10

Lead Sponsor: Pamela Munster

Target Recruit Count: 23

Registration Number: NCT02358200

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Solid Tumors

Interventions: Drug: PZP115891, PCI-24781

First Posted Date: 2012-03-05

Last Posted Date: 2024-02-29

Lead Sponsor: Pamela Munster

Target Recruit Count: 90

Registration Number: NCT01543763

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy